Bayer's Workforce Shrinks by 12,000 Following Restructuring

Bayer has confirmed it has cut around 12,000 full-time jobs globally since it began its restructuring programme, as per news reports. This is part of a broader plan to reduce layers in management and administration and to speed up internal decision-making. A previous count of job cuts for 2024 had stood at 7,000.

Employee Strength Now Near 90,000

As of the end of June 2025, Bayer’s total workforce stood close to 90,000 when counted in full-time equivalents, according to the company’s latest quarterly report. The restructuring drive remains ongoing, with no new timeline or headcount targets disclosed in this update.

Additional Provisions for Roundup Litigation

Bayer has also added €1.2 billion in fresh provisions to cover ongoing US lawsuits related to its Roundup weedkiller. This brings the total amount set aside for Roundup litigation to €6.3 billion, or about $7.4 billion. The company reiterated that it may need to halt U.S. production of glyphosate, a key ingredient in Roundup, if no regulatory or legal relief is provided.

As per news reports, despite pressure from some shareholders, Bayer has stated that it is not planning to spin off or list its consumer health or crop science units separately at this stage. The group remains diversified across pharma, crop science, and consumer health businesses.

Leverkusen Transfer Boost and Older Drugs

As per news reports, Bayer also noted a financial boost from player transfers by its football club, Bayer Leverkusen. Media reports suggest a €136.3 million deal with Liverpool for Florian Wirtz, though Bayer declined to confirm this. Separately, revenue growth was also linked to older products like blood thinner Xarelto rather than newer drugs.

Read More: Tech Job Cuts: Intel to Cut 25,000 Jobs, Targets 75,000 Workforce by End 2025!

Conclusion

Bayer’s restructuring push has led to significant job cuts and higher legal provisions, with no immediate changes to its group structure.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.